Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Madrigal Pharmaceuticals Inc

Healthcare US MDGL

432.78USD
-0.42(0.10%)

Last update at 2026-03-10T20:00:00Z

Day Range

430.21443.42
LowHigh

52 Week Range

119.76299.98
LowHigh

Fundamentals

  • Previous Close 433.20
  • Market Cap4828.97M
  • Volume254461
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-453.62598M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-23.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -295.35000M -241.84600M -202.24400M -83.94800M -32.81100M
Minority interest - - - - -
Net income -299.31400M -241.07800M -197.44400M -72.81200M -32.81100M
Selling general administrative 48.13M 37.32M 21.86M 22.65M 15.29M
Selling and marketing expenses - - - - -
Gross profit - 0.27M 0.02M - 0.20M
Reconciled depreciation 0.47M 0.41M 0.47M 0.11M 0.10M
Ebit -293.57100M -242.88700M -207.14400M -95.08400M -40.77800M
Ebitda -291.38600M -242.48200M -206.67300M -94.97200M -40.68200M
Depreciation and amortization 2.19M 0.41M 0.47M 0.11M 0.10M
Non operating income net other 2.19M 0.36M 4.33M 11.02M 7.67M
Operating income -293.57100M -242.48200M -206.67300M -94.97200M -40.68200M
Other operating expenses 293.57M 242.48M 206.67M 94.97M 40.68M
Interest expense 3.96M 1.04M 4.33M 11.02M 7.67M
Tax provision - - - - -
Interest income 2.19M 0.36M 4.33M 11.02M 7.67M
Net interest income -1.77900M 0.36M 4.33M 11.02M 7.67M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.96M -0.76800M -4.80000M -11.13600M 7.87M
Total revenue 0.00000M 0.04M 0.02M 0.00000M 0.20M
Total operating expenses 293.57M 242.48M 206.67M 94.97M 40.68M
Cost of revenue - - - - 0.00000M
Total other income expense net -1.77900M 0.64M 4.43M 11.02M 0.20M
Discontinued operations - - - - -
Net income from continuing ops -295.35000M -242.11900M -202.34400M -83.94800M -33.01100M
Net income applicable to common shares -295.35000M -241.84600M -202.24400M -83.94800M -32.81100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 640.55M 362.57M 273.33M 287.00M 442.06M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.15M 2.60M 1.34M 1.01M 1.15M
Total liab 235.21M 165.18M 77.22M 47.02M 25.49M
Total stockholder equity 405.33M 197.39M 196.11M 239.97M 416.56M
Deferred long term liab - - - - -
Other current liab 89.98M 91.46M 55.05M 45.22M 23.64M
Common stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Capital stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00200M
Retained earnings -1336.29000M -962.66000M -667.31000M -425.46400M -223.22000M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - - -
Cash 99.92M 331.55M 36.27M 54.00M 46.70M
Cash and equivalents - - - - -
Total current liabilities 118.55M 115.89M 76.84M 46.56M 25.13M
Current deferred revenue - - - - -
Net debt 17.28M -281.65800M -35.47200M -53.21800M -46.02100M
Short term debt 0.53M 0.60M 0.41M 0.32M 0.32M
Short long term debt - - - - -
Short long term debt total 117.19M 49.89M 0.80M 0.79M 0.68M
Other stockholder equity 1741.15M 1160.08M 863.50M 665.38M 639.57M
Property plant equipment - 0.60M 1.65M 1.05M 1.18M
Total current assets 637.28M 361.37M 271.68M 285.16M 440.20M
Long term investments - - - - -
Net tangible assets - 197.39M 196.11M 239.97M 416.56M
Short term investments 534.22M 27.23M 234.08M 230.15M 392.35M
Net receivables - - - - -
Long term debt 115.48M 49.29M - - -
Inventory - - - - -
Accounts payable 28.04M 23.83M 21.38M 1.02M 1.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.47M -0.03200M -0.08000M 0.05M 0.22M
Additional paid in capital - - - - -
Common stock total equity - 0.00200M 0.00200M 0.00200M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -962.66000M -667.31000M -425.46400M -223.22000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 1.20M 0.80M 1.83M 1.86M
Deferred long term asset charges - - - - -
Non current assets total 3.27M 1.20M 1.65M 1.83M 1.86M
Capital lease obligations 1.71M 0.60M 0.80M 0.79M 0.68M
Long term debt total - 49.29M - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -502.52000M 206.69M -4.84600M 160.11M 30.88M
Change to liabilities - 38.86M 20.36M 21.42M 15.47M
Total cashflows from investing activities - 206.69M -5.05500M 159.78M 30.71M
Net borrowings - 49.11M 50.00M 50.00M 50.00M
Total cash from financing activities 595.12M 313.45M 171.24M 5.09M 0.23M
Change to operating activities - 35.15M 10.29M 23.64M 20.76M
Net income -373.63000M -295.35000M -241.84600M -202.24400M -83.94800M
Change in cash -231.63400M 295.28M -17.73500M 7.31M -10.68200M
Begin period cash flow 331.55M 36.27M 54.00M 46.70M 57.38M
End period cash flow 99.92M 331.55M 36.27M 54.00M 46.70M
Total cash from operating activities -324.23000M -224.85700M -183.91700M -157.56100M -41.62400M
Issuance of capital stock 260.19M 255.38M 170.21M 4.42M 0.00000M
Depreciation 0.53M 0.47M 0.41M 0.47M 0.11M
Other cashflows from investing activities - - - - 30.88M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - 0.23M
Other cashflows from financing activities -0.36300M 107.18M 1.03M 0.67M 0.00023M
Change to netincome - 31.62M 26.87M 20.73M 22.76M
Capital expenditures 1.48M 0.22M 0.21M 0.33M 0.17M
Change receivables - - - - -
Cash flows other operating - -1.26000M 0.46M 2.06M 3.98M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 295.28M -17.73500M 7.31M -10.68200M
Change in working capital -3.27600M 37.60M 30.65M 23.48M 19.45M
Stock based compensation 49.73M 31.62M 26.87M 20.73M 22.76M
Other non cash items 6.62M 0.80M 7.32M 21.83M 24.29M
Free cash flow -325.70900M -225.07400M -184.12600M -157.89500M -41.79600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MDGL
Madrigal Pharmaceuticals Inc		 -0.42 0.10% 432.78 - - - 12.24 -12.3331
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc

Four Tower Bridge, West Conshohocken, PA, United States, 19428

Key Executives

Name Title Year Born
Dr. Paul A. Friedman M.D. Chairman & CEO 1943
Dr. Rebecca A. Taub M.D. Founder, Chief Medical Officer, Pres of R&D and Director 1952
Mr. Alex G. Howarth Sr. VP & CFO 1969
Mr. Brian J. Lynch J.D. Sr. VP & Gen. Counsel 1962
Mr. Remy Sukhija Sr. VP & Chief Commercial Officer 1972
Dr. Kianoush Motesharei Ph.d. Sr. VP of Bus. & Corp. Devel. 1970
Mr. Edward Chiang Sr. VP of Clinical & Technical Operations NA
Mr. Thomas W. Hare Sr. VP of Clinical Management NA
Dr. Robert E. Waltermire Ph.D. Chief Pharmaceutical Devel. Officer 1964
Dr. Stephen Dodge M.B.A., Pharm.D. Sr. VP of Global Medical Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.